Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + rosuvastatin (LG Chem)
- Development stage
- Unknown
- Lead developer
- LG Chem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rovatitan is a fixed-dose combination (FDC) tablet developed by LG Chem (formerly LG Life Sciences) for the management of patients with concurrent hypertension and hyperlipidemia (dyslipidemia). It combines two small molecule active ingredients: valsartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to promote vasodilation and reduce blood pressure, and rosuvastatin calcium, a potent HMG-CoA reductase inhibitor (statin) that lowers low-density lipoprotein (LDL) cholesterol and triglycerides. The combination is designed to improve patient compliance by reducing the daily pill burden in individuals requiring treatment for both cardiovascular risk factors. Rovatitan is available in multiple dosage strengths and was first approved and marketed in South Korea.
- Brand names
- Rovatitan
- Other names
- valsartan/rosuvastatin fixed-dose combination
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on valsartan + rosuvastatin (LG Chem).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + rosuvastatin (LG Chem).